“DelveInsight’s, “Heart Failure Pipeline Insight, 2022,” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in the Heart Failure pipeline landscape”
It covers the Heart Failure Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Heart Failure emerging drugs, the Heart Failure pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Heart Failure pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Heart Failure Pipeline Insight Report
- DelveInsight’s Heart Failure Pipeline analysis depicts the space with 90+ active players working to develop 90+ pipeline therapies.
- The Heart Failure pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
- Heart Failure Pipeline Companies included Bayer HealthCare Pharmaceuticals, Ionis Pharmaceuticals, Heartseed Inc., AstraZeneca, Amgen, Sardocor Corp, Intra-Cellular Therapies, Bristol Myers Squibb, Eli Lilly and Company, Palatin Technologies, Cardiora, Zensun Sci. & Tech. Co., Ltd., and many others.
- Heart Failure Pipeline Companies included Omecamtiv mecarbil, Tirzepatide, IONIS AGT LRx, JK-07, TN301, and many others
Get to know more in-depth information about the Heart Failure Pipeline Report, click here: Heart Failure Pipeline Insight
Heart Failure Overview
Heart failure is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Heart failure can severely decrease the functional capacity of a patient and increase mortality risk. It is imperative to diagnose and effectively treat the disease to prevent recurrent hospitalizations, improve quality of life, and enhance patient outcomes.
The heart failure treatment requires a multifaceted approach involving patient education, optimal medical regimen to improve cardiac contractility, and prevention/limitation of exacerbations. The most important consideration when categorizing heart failure is whether left ventricular ejection fraction (LVEF) is preserved or reduced (less than 50 percent). A reduced LVEF in systolic heart failure is a powerful predictor of mortality. The common symptoms of congestive heart failure include fatigue, dyspnea, swollen ankles, and exercise intolerance, or symptoms that relate to the underlying cause. Patients with heart failure present with a variety of symptoms, most of which are non-specific.
Heart Failure Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines. The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
- Tirzepatide: Eli Lilly and Company
- Finerenone (BAY94-8862): Bayer
- CardiAMP Cell Therapy: BioCardia
- Rexlemestrocel-L (Revascor): Mesoblast
- BMS-986231: Bristol-Myers Squibb
- Elamipretide: Stealth BioTherapeutics
- FA relaxin: Bristol Myers Squibb
There are approx. 90+ key companies which are developing therapies for Heart Failure. The companies which have their Heart Failure drug candidates in the most advanced stage, i.e. Phase III include Eli Lilly and Company.
For further information about Heart Failure Treatment and pipeline therapies, visit @ Heart Failure Pipeline Assessment
DelveInsight’s Report covers around 90+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Heart Failure Pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Heart Failure
- Heart Failure key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Heart Failure
The Heart Failure Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Table of Content
- Executive Summary
- Heart Failure Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Heart Failure – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tirzepatide: Eli Lilly and Company
- Mid Stage Products (Phase II)
- AZD-8601: AstraZeneca
- Early Stage Products (Phase I/II)
- Drug name: Company name
- Early Stage Products (Phase I)
- AZD-3427: AstraZeneca
- Preclinical and Discovery Stage Products
- RBM-003: Ribomic
- Inactive Products
- Heart Failure Key Companies
- Heart Failure Key Products
- Heart Failure – Unmet Needs
- Heart Failure – Market Drivers and Barriers
- Heart Failure – Future Perspectives and Conclusion
- Heart Failure Analyst Views
- Heart Failure Key Companies
Got Queries? Reach out for more information on the Heart Failure Pipeline Report- Heart Failure Clinical Trials
You may explore our latest Pharmaceutical Market Research Reports
- Rubella Market
- Schistosomiasis Market
- Lambert-Eaton Myasthenic Syndrome Market
- Hypertrophic Cardiomyopathy Market
- Thyroid Cancer Market
- Heart Pump Device Market
- Scabies Market
- Coronary Stents Pipeline
- Immune Thrombocytopenia Market
- Short Bowel Syndrome Drug Market
- Peanut Allergy Market
- Small lymphocytic lymphoma Market
- Surgical Energy Instruments Market
- Pulmonary Arterial Hypertension Market
- Novel Drug Delivery Devices Market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: [email protected]
Address: 304 S. Jones Blvd #2432
City: Las Vegas
Country: United States